Key Takeaways
- Standalone revenue surged 76% YoY to INR 1,357 crores, driven by volume growth and a richer product mix as CBE climbed from 10% to 30% of the top line over two years.
- Consolidated gross margin fell 500 bps QoQ to 43% as nine new subsidiaries booked first-year setup and freight costs; management calls these transitional and expects normalization as operations scale.
- A Burkina Faso backward-integration MoU promises to strip out 45–60% of raw-material logistics cost by crushing seeds at origin, a structural margin lever once commissioned.
- Capacity is being pulled forward fast: solvent fractionation debottlenecking added 30% more throughput, and a INR 460 crores capex program targets commissioning by FY28 to support the 25–30% growth ambition.
- What to watch next quarter: whether consolidated margins begin the promised normalization, any concrete QIP parameters, and the pace of subsidiary scale-up.
Top-Line Growth & Volume Engine
- Volume-led expansion: FY26 volume growth was 80–90% while price contributed only 5–10%, confirming the story is capacity-driven rather than price-driven.
- CBE mix shift: The cocoa butter equivalent share of revenue moved from 10% to 30% over two years, lifting realizations and margins alongside higher plant utilization.
- FY27 growth ambition: Management targets 20–30%+ volume growth and a 5% price hike, aiming for 25–30% overall revenue growth, a rate it calls "the company aim" and is confident in achieving given coming capacities.
- Long-term revenue target: The company is confident of exceeding INR 3,500 crores by FY30 with the capacity build-out underway.
Ekta Soni: "It's not a thing that there will be there. Of course, the company is very poised and fuelled for the growth, given the capacity we have."
Margin Bridge & Subsidiary Drag
- Standalone margin held firm: Standalone gross margin was flat QoQ, while the consolidated figure dropped from 48% to 43% solely because of newly incorporated subsidiaries in their first operating year.
- Subsidiary cost composition: The drag came from initial setup costs, employee costs, establishment expenses, freight, and other production-related costs at the subsidiary level. Management categorizes these as one-time or transitional.
- Normalization expected: As the nine subsidiaries scale, margins are expected to stabilize; management requests shareholders evaluate margins on a year-on-year basis rather than quarter-to-quarter.
- Sustainable margin range: The company guides to 45–50% gross margin and 25–27% EBITDA margin over the cycle, with no downward pressure expected from current levels.
- 230 bps standalone EBITDA expansion was delivered in FY26 through product mix improvement and higher plant utilization.
Ekta Soni: "We try to maintain on quarter-to-quarter basis, but whatever guidance we try to give, we will request our shareholders to take on year-on-year basis."
Capacity Expansion & Capex
- Debottlenecking delivered: Solvent fractionation plant 2 was expanded 30% from 25,000 to 32,500 TPA, taking total fractionation capacity to 47,500 tons. The remaining 4,500 tons of debottlenecking is underway in the current fiscal year.
- Plant 1 debottlenecking: A similar exercise is planned for the 15,000 MT solvent fractionation plant 1 this fiscal year.
- Forward-integration projects: A CBA plant, a 75,000-ton solvent fractionation 3 plant, and a 90,000 MT per annum refinery are expected to carry the same or better margins once ramped up.
- INR 460 crores capex will be spent in a phased manner over 2–3 years, with all projects targeted for commissioning by FY28. Funding has begun through internal accruals, supported by a free cash FD of INR 130 crores.
- Utilization headroom: Existing capacity is at 85% of 40,000 tons; the company targets 85–90% utilization of the full 52,000 TPA capacity in the current fiscal year.
Burkina Faso & Raw Material Strategy
- Backward integration MoU: A government-backed project with Burkina Faso will establish crushing and processing at origin, eliminating 45–60% of raw-material logistics cost and improving butter yield by processing seeds immediately rather than after 60 days.
- INR 350 crores investment will fund the Burkina Faso processing facility; butters will be shipped to India for further value addition through fractionation.
- Indian plant optimization: The existing 90,000-ton solvent extraction facility in India will be better optimized for Indian exotic seeds (Sal and Mango) once Burkina Faso volumes flow.
- Geopolitical insulation: Key raw materials (Sal, Mango, Shea) are not sourced from West Asia, Russia, or Ukraine, and revenue exposure to those regions is minimal. Indirect impact is limited to energy prices, freight costs, and currency volatility.
- Political risk addressed: Management stated that political uncertainty in Africa does not affect operations because the Burkina Faso project is government-backed.
Ekta Soni: "Given the parlance metrics of the business, if the political uncertainty or insecurity, it does not really affect our operation in Africa. It is a government-backed project for which we have already signed the MoU with government of Burkina Faso."
Balance Sheet & Cash Flow
- Operating cash flow reached INR 259 crores, described as a significant milestone for the business.
- Working capital days improved to 125 from 151, with management confident of sustaining current levels.
- Inventory composition: Total inventory of INR 710 crores breaks down into INR 420 crores raw material, INR 260 crores finished goods, and INR 30 crores WIP/co-products, forming the base for the coming year's revenue.
- QIP enabling resolution: Approved for up to INR 500 crores through permissible modes; management is evaluating options and will disclose when parameters are finalized. The resolution is separate from the capex funding plan, which currently relies on internal accruals.
- Dekel arrangement (Brazil): A pure processing-cost model with no profit-sharing; the company pays per metric ton as processing occurs, not upfront. Operations are still scaling.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 25–30% overall, with 20–30%+ volume growth and ~5% price hike | FY27 |
| Capacity utilization | 85–90% of 52,000 TPA fractionation capacity | FY27 |
| Capex program completion | INR 460 crores spent; all projects commissioned | By FY28 |
| Long-term revenue | More than INR 3,500 crores | By FY30 |
| Sustainable margin range | 45–50% gross margin, 25–27% EBITDA margin | Ongoing, judged year-on-year |
| Subsidiary margin normalization | Margins expected to stabilize as operations scale | No date; transitional costs are first-year |
| Working capital | Maintain current days and inventory days | Ongoing |
| Plant 1 debottlenecking | 15,000 MT solvent fractionation plant expansion | Current fiscal year |
| Remaining debottlenecking | 4,500 tons of fractionation capacity to be streamlined | Current financial year |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Stand-alone revenue | ₹382.3 cr, FY26 total ₹1,357 cr, up 76.1% YoY |
| EBITDA | ₹102.9 cr, margin 26.9% |
| PAT | ₹59.5 cr, margin 15.6% |
| Net foreign exchange loss | ₹7.58 cr (stand-alone), MTM provision ₹17.05 cr offset by forex income ₹9.47 cr |
| EBITDA margin (FY26 full year) | 27.1%, up 230 bps YoY driven by product mix and higher utilization |
| Volume growth (FY26) | 80–90% YoY, with 5–10% price growth |
| CBE revenue contribution | ~30% of top line, up from 10% two years ago |
| Value-added product mix (CBE + stearin) | 70–75% of total sales |
| Fractionation capacity utilization | 85% on 40,000 TPA base (excludes debottlenecking) |
| Stearin volume (FY26) | ~8,000 metric tons |
| CBE volume (FY26) | ~7,500 metric tons |
| Working capital days | 125 days (FY26), improved from 151 days in FY25 |
| Net debt-to-equity ratio | 0.38:1 as of 31 March 2026 |
| ROE | 40.3% as of 31 March 2026 |
| ROCE | 33.6% as of 31 March 2026 |
| Operating cash flow (FY26) | ₹259.4 cr |
| Capex commitment | ~₹460 cr over next 2–3 years, ₹52 cr already spent |
| Raw material sourced from Manorama Africa | 20–25% in FY26, down from 60% last year |
| Consolidated EBITDA margin (FY26) | ~26%, vs 27% standalone, impacted by subsidiary setup costs |
| Export revenue share | 57% of total revenue |
| Forex hedged | ~60% of net exposure through forward contracts |